Absence of association between the MCP-1 gene polymorphism and histological phenotype of lupus nephritis

Lupus

Volumn 13, Issue 3, 2004, Pages 165-167

  Nakashima, Hitoshi ^a   Akahoshi, M ^b   Shimizu, S ^a   Inoue, Y ^a   Miyake, K ^a   Ninomiya, I ^a   Igawa, T ^a   Sadanaga, A ^a   Otsuka, T ^a   Harada, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

Gene polymorphism; MCP 1; Membranous glomerulonephritis (WHO class V); Proliferative glomerulonephritis (WHO class IV); SLE

Indexed keywords

CHEMOATTRACTANT; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CELL ADHESION; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; GLOMERULUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; INTERSTITIUM; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

EID: 11144354765     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu523oa     Document Type: Article

References (26)

1. Klinman DM, Steinberg AD. Inquiry into murine and human lupus. Immunol Rev 1995; 144: 157-193.
2. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390.
3. Dixon FJ. The pathogenesis of glomerulonephritis. Am J Med 1968; 44: 493-498.
4. Chrug J, Berntein J, Glasock RJ. Lupus nephritis. In Chrug J, Berntein J, Glasock RJ eds. Renal diseases: classification and atlas of glomerular disease. New York: Igaku-Shoin, 1995; 151-180.
5. Kashgarian M. Lupus nephritis: pathology, pathogenesis, clinical correlations, and prognosis. In Wallace DT, Hahn BH eds. Dubois' lupus erythematosus, 5th edition. Philadelphia: Williams and Willkins, 1997; 1037-1051.
6. Masutani K, Akahoshi M, Ninomiya T et al. Predominance of Th1 type immune responses in human diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097-2106.
7. Valente AJ, Graves DT, Vialle-Valentin, CE, Delgado R, Schwartz CJ. Purification of monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 1988; 27: 4162-4168.
8. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein-1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994; 91: 3652-3656.
9. Allavena P, Bianchi G, Zhou D et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994; 24: 3233-3236.
10. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokinereceptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11: 152-176.
11. Rovin BH, Rumancik M, Tan L, Dickerson J. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994; 71: 536-542.
12. Wada T, Yokoyama H, Su SB et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49: 761-767.
13. Wada T, Furuichi K, Segawa-Takaeda C et al. MIP-1 alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999; 56: 995-1003.
14. Rovin BH, Phan LT. Chemotactic factors and renal inflammation. Am J Kidney Dis 1998; 31: 1065-1084.
15. Zoja C, Liu XH, Donadelli R et al. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice J Am Soc Nephrol 1997; 8: 720-729.
16. Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996; 27: 640-646.
17. Noris M, Bernasconi S, Casiraghi F et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995; 73: 804-809.
18. Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, Tomino Y. Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy. J Clin Lab Anal 1989; 3: 355-359.
19. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997; 186: 131-137.
20. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas lpr mice. J Exp Med 1999; 190: 1813-1824.
21. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259: 344-348.
22. Rovin BH, Phan LT. Chemotactic factors and renal inflammation. Am J Kidney Dis 1998; 31: 1065-1084.
23. Strieter RM, Koch AE, Antony VB, Fick RB Jr, Standiford TJ, Kunkel SL. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994; 123: 183-197.
24. Antoniades HN, Neville-Golden J, Galanopoulos T, Kradin RL, Valente AJ, Graves DT. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 1992; 89: 5371-5375.
25. Koch AE, Kunkel SL, Harlow LA et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90: 772-779.
26. Grandaliano G, Gesualdo L, Ranieri E et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 1996; 7: 906-913.